hyperprolactinaemia is compatible with the concept of a reduced dopaminergic tonus as the mechanism for both changes. In patients with advanced hyperprolactinaemia and sellar enlargement the high prolactin level may induce some inhibition of TSH release and explain their lower basal serum level of TSH that was probably not due to pituitary compression as they responded normally to TRH.
The TSH response to TRH was significantly (P < 0.05) correlated to the basal serum TSH in all groups. The regression lines were very similar for hyperprolactinaemic patients and controls suggesting that in hyperprolactinaemia the thyrotroph has not changed its mode of response to TRH. In contrast, oestrogen treated subjects in addition to dependence on basal serum TSH levels showed a genuinely augmented response to TRH (164.6 \ m=+-\20.3%, P < 0.01) compared to controls.
The serum level of TSH (S-TSH) and its response to TRH may be affected by factors that are not related to thyroid or pituitary dysfunction. Thus the TSH response to TRH is known to be influenced by dopaminergic mechanisms. It has been reported to be blunted by the administration of L-dopa (Spaulding et al. 1972; Besses et al. 1975) while basal S-TSH levels are increased in euthyroid and hypothyroid subjects by metoclopramide (Aoki et al. 1976; Healy & Burger 1977; Scanlon et al. 1977) or domperidone (Delitala et (Pekary et al. 1975 ). The intra-assay variation was 7.8%, the inter-assay variation 14.7%. The radio¬ ligand assays for S-T3, S-T4 and P-prolactin showed intra-and inter-assay variations of less than 7.5%.
Results
The hormone levels in the different groups are summarized in (Fine & Frohman 1978; Van Loon 1978) , and in healthy subjects an acute reduction of dopaminer¬ gic impulses by domperidone increased S-TSH and P-prolactin in parallel (Scanlon et al. 1981 ). How¬ ever, in patients with hyperprolactinaemia given domperidone the increase in S-TSH was exaggera¬ ted compared to controls while the increase in P-prolactin was blunted (Scanlon et al. 1981 ). This was interpreted as a feed back effect by prolactin leading to an augmented dopaminergic inhibition of TSH release. In our hyperprolactinaemic pa¬ tients and in those of Völker & v z Mühlen (1979) as well the elevated S-TSH levels were found predominantly in patients without sellar enlarge¬ ment and with moderately increased P-prolactin while those with X-ray signs of pituitary tumour and much higher P-prolactin had lower S-TSH that did not differ from control.
A lowered S-TSH under bromergocryptine treatment gives no clue to the mechanism of the elevated S-TSH in hyperprolactinaemia as dopa¬ minergic stimulation lowers also the high S-TSH in primary hypothyrodism (Rapoport et al. 1973 
